InspireMD (II2) Q2 2026 Earnings Report

The call presented a mix of encouraging operational and regulatory progress (21% international revenue growth, constructive FDA interactions, multiple potential approvals, enrollment in a pivotal SwitchGuard study, and planned annualized cost savings of ~$9 million) alongside significant near‑term challenges (voluntary recall driving $734k in customer credits and a $612k inventory impairment, a swing to negative GAAP gross margin, a wider net loss of $14.3M, and a substantial cash decline from $54.2M to $30.4M). Management articulated a clear remediation and relaunch plan and emphasized underlying demand, but financial impacts and regulatory timing risk keep the outlook balanced between opportunity and near‑term execution/liquidity challenges.

Management provided multi‑pronged guidance focused on regulatory and commercial milestones: potential FDA decisions in Q4 2026 for CGuard Prime 80 (TCAR) and the original CGuard CAS platform, targeted market re‑entry for the redesigned CGuard Prime 135 in H1 2027 (possible earlier approval), and a SwitchGuard pivotal program aiming toward a H2 2027 U.S. approval/launch; if approvals occur, the company expects to address roughly 75,000 annual U.S. stenting procedures and says Prime 80 would roughly double its addressable market. Financial and operational metrics/guidance included Q2 FY2026 results of total revenue $1.8M (international revenue $2.1M, +21% YoY), a Q2 gross loss of $0.8M (‑43.7% of revenue) driven by a $734k customer credit and $612k inventory impairment (adjusted non‑GAAP gross profit $0.6M), operating expenses $13.7M, net loss $14.3M (‑$0.17/share), cash & marketable securities $30.4M (6/30/26), a ~20% workforce reduction expected to save ~$9M annually with a Q3 restructuring charge of $0.9–1.2M, and most cost savings expected to be realized by Q4 2026.